CDC launches hypertension control challenge

The Centers for Disease Control and Prevention (CDC) has launched the Million Hearts Hypertension Control Challenge, which is part of a Department of Health and Human Services effort to prevent 1 million heart attacks and strokes by 2017.

The challenge, which runs through Oct. 10, asks clinicians, clinical practices or health systems to share their health IT approaches to improving blood pressure management, as well as their integrating team-based approaches to care and community approaches like improving tobacco control and lowering sodium consumption.

CDC is requesting the following as part of the submission process:

  • Submission of two point-in-time measures of the population’s hypertension control rate: one for the previous 12-month period and the other for the previous 12 to 24 months;
  • Data on the population's prevalence of hypertension;
  • Systems used by the providers to control hypertension in its adult patient population; and
  • The size and demographics of its patient population.

Up to 20 providers will be recognized as part of the CDC challenge. A total of $40,000 will be divvied out, according to a Federal Register notice.

This challenge runs parallel to another effort launched earlier this summer by the Office of the National Coordinator for Health IT (ONC). This agency is seeking out providers’ most effective evidence-based treatment protocols to guide the selection of effective therapies for blood pressure control.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.